Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice

Carolina Vicente-Dueñas; Marcos Barajas-Diego; Isabel Romero-Camarero; Ines Gonzalez-Herrero; Teresa Flores; Isidro Sanchez-Garcia

doi:10.18632/oncotarget.461

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Brief Reports:

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice

Carolina Vicente-Dueñas, Marcos Barajas-Diego, Isabel Romero-Camarero, Ines Gonzalez-Herrero, Teresa Flores and Isidro Sanchez-Garcia _

PDF | HTML | How to cite

Oncotarget. 2012; 3:261-266. https://doi.org/10.18632/oncotarget.461

Metrics: PDF 3276 views | HTML 3338 views | ?

Abstract

Carolina Vicente-Dueñas^1,2, Marcos Barajas-Diego^1,2, Isabel Romero-Camarero^1,2, Inés González-Herrero^1,2, Teresa Flores^2,3, and Isidro Sánchez-García^1,2

¹ Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/ Universidad de Salamanca, SALAMANCA, (SPAIN)

² Institute of Biomedical Research of Salamanca (IBSAL)

³ Departamento de Anatomía Patológica, Universidad de Salamanca

Received: February 29, 2012; Accepted: March 2, 2012; Published: March 8, 2012;

Keywords: cancer, cancer stem cells (CSC), stem cells, mouse models, Telomerase inhibitors, drug discovery

Correspondence:

Isidro Sánchez-García,

Abstract

The telomerase protein is constitutively activated in malignant cells from many patients with cancer, including the chronic myeloid leukemia (CML), but whether telomerase is essential for the pathogenesis of this disease is not known. Here, we used telomerase deficient mice to determine the requirement for telomerase in CML induced by BCR-ABL in mouse models of CML. Loss of one telomerase allele or complete deletion of telomerase prevented the development of leukemia induced by BCR-ABL. However, BCR-ABL was expressed and active in telomerase heterozygous and null leukemic hematopoietic stem cells. These results demonstrate that telomerase is essential for oncogene-induced reprogramming of hematopoietic stem cells in CML development and validate telomerase and the genes it regulates as targets for therapy in CML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 461

Publication Alerts

Post-Publication Promotion

Publication Discount

Brief Reports:

Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice

Abstract